Gene therapy company Voyager Therapeutics has received a milestone payment of $25 million after Novartis exercised its options to license two novel capsids. 6 March 2023
US biopharma company Incyte announced late Friday that it will discontinue its Phase III LIMBER-304 trial, sending its share price 2% lower early in Monday’s tr 6 March 2023
Cell and gene therapy manufacturing company eXmoor pharma and vaccine developer Imophoron have agreed a strategic process development partnership that includes 24 February 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.